Back to top

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer ...

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvic

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Actinium Pharmaceuticals, Inc. (ATNM)